CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Acquired by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMXGet Rating) by 175.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 235,470 shares of the biotechnology company’s stock after purchasing an additional 150,091 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.36% of CytomX Therapeutics worth $429,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of CytomX Therapeutics by 2.2% during the first quarter. Vanguard Group Inc. now owns 5,222,886 shares of the biotechnology company’s stock valued at $13,945,000 after acquiring an additional 114,895 shares during the period. BlackRock Inc. increased its stake in shares of CytomX Therapeutics by 0.6% in the first quarter. BlackRock Inc. now owns 4,992,094 shares of the biotechnology company’s stock valued at $13,328,000 after purchasing an additional 29,732 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of CytomX Therapeutics during the first quarter valued at approximately $3,446,000. Renaissance Technologies LLC boosted its position in shares of CytomX Therapeutics by 77.2% during the first quarter. Renaissance Technologies LLC now owns 895,900 shares of the biotechnology company’s stock worth $2,392,000 after buying an additional 390,400 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in CytomX Therapeutics by 115.2% in the 1st quarter. Acadian Asset Management LLC now owns 885,107 shares of the biotechnology company’s stock worth $2,362,000 after buying an additional 473,885 shares in the last quarter. 84.38% of the stock is currently owned by institutional investors.

CytomX Therapeutics Stock Performance

NASDAQ CTMX opened at $1.25 on Tuesday. The firm’s 50 day moving average price is $1.45 and its two-hundred day moving average price is $1.58. CytomX Therapeutics, Inc. has a twelve month low of $1.19 and a twelve month high of $7.53. The stock has a market cap of $82.44 million, a price-to-earnings ratio of -0.84 and a beta of 0.38.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CTMX shares. HC Wainwright lowered CytomX Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, July 11th. StockNews.com started coverage on shares of CytomX Therapeutics in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Cowen lowered CytomX Therapeutics to a “market perform” rating in a research note on Tuesday, July 19th. Finally, Cowen lowered CytomX Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, July 11th. Eight analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.89.

About CytomX Therapeutics

(Get Rating)

CytomX Therapeutics, Inc engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W.

Further Reading

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.